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We have investigated the molecular diversity of Hepatitis B virus (HBV) among the HIV co-infected
patients from eastern-India. HBsAg/HBV-DNA positive subjects (n¼73) from 874 HIV-infected patients
were analyzed by sequencing followed by genetic diversity quantiﬁcation. HBV/genotype-D and HBV/
sugenotype-D2 were predominant. HBV/D2 isolates from patients with low CD4 count manifested
signiﬁcantly lower non-synonymous substitutions (po0.0001) and Shannon entropy (p¼0.0006) in
their surface and polymerase gene in comparison to those from moderately increased CD4 count. ART-
induced immune-reconstitution therefore might raise non-synonymous immune/therapy escape
substitutions among these HBV/D2 isolates. Decreased genetic diversity and increased viral load in
the HBV/D2 isolates might facilitate the maintenance of their wild type characteristics in the low CD4
count, leading to its increased prevalence in this group. Interestingly, genetic diversity in HBV/A1, the
next common subgenotype, was modiﬁed in the opposite manner. Together our results underscore the
need for proper HBV molecular monitoring in HIV co-infection.
& 2012 Elsevier Inc. All rights reserved.Introduction
Introduction of highly active anti-retroviral therapy (HAART)
in late 20th century has decreased AIDS-related morbidity and
mortality. Thus liver diseases associated with chronic hepatitis
have emerged as the second leading cause of death among the
HIV-infected patients (Lacombe et al., 2010). According to
UNAIDS report (2009), people living with HIV infection is esti-
mated to be 33.3 million in the world (/http://www.unaids.org/
documents/20101123_GlobalReport_Chap2_em.pdfS). Globally,
350–400 million people are chronic Hepatitis B surface antigen
(HBsAg) carriers (Datta, 2008). In addition, shared routes of
transmission have led 3 million people around this world to be
co-infected with HIV and hepatitis B virus (HBV) (Soriano et al.,
2010). Several studies have reported that HIV related immunell rights reserved.
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6, Haryana, India.suppression signiﬁcantly modiﬁes the natural history of HBV
infection (Vallet-Pichard and Pol, 2004; Puoti et al., 2006). The
presence of HIV is associated with increased chronicity of HBV
infection, reduced rate of spontaneous HBsAg and hepatitis B early
antigen (HBeAg) seroconversion (Thio, 2009). End-stage liver dis-
eases (ESLDs) such as cirrhosis and hepatocellular carcinoma (HCC)
( Lacombe et al., 2006; Salmon-Ceron et al., 2009) and liver related
mortality were also found to be increased considerably in the HIV
co-infected patients compared to HBV mono-infection (Thio et al.,
2002). Moreover, the presence of HIV and consequential immune
alterations may act as cofactors in modulating HBV genetic varia-
bility as well as its molecular evolution within a HIV co-infected
host. However, reports which have addressed this issue are scanty.
Recently, HIV co-infection has been reported to be associated with
the emergence of speciﬁc mutations in the HBV genome (Audsley
et al., 2010). HIV driven immune dysfunction also renders low
evolutionary rate to HBV (Cassino et al., 2012). Therefore, the role
of HIV driven immune dysfunction in the molecular heterogeneity
of HBV during coexistence in a host requires further investigation.
Based on 48% divergence in the complete genome sequence
eight HBV genotypes (HBV/A to HBV/H) have been classiﬁed and
two more genotypes (HBV/I and HBV/J) have been proposed
recently (Lin and Kao, 2011). In addition, based on 44% (but
o8%) divergence in the complete nucleotide sequence within a
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genotypes and subgenotypes vary geographically and differ con-
siderably in the mutational patterns, ethnicity and associated
clinical outcomes. In India, HBV/D is predominant, with varying
prevalence of HBV/A in different parts of the country (Datta,
2008). In eastern India HBV/C is also circulating in a considerable
proportion. Moreover, four subgenotypes were identiﬁed within
HBV/D (HBV/D1, HBV/D2, HBV/D3 and HBV/D5) and only one
subgenotype was found in HBV/A (HBV/A1) and HBV/C (HBV/C1)
each in this part of the country.
The epidemic spread of HIV has made India the third largest
population with this infection in the world next only to South Africa
and Nigeria (/http://www.unaids.org/en/dataanalysis/monitoring
countryprogress/progressreports/2010countries/india_2010_country_
progress_report_en.pdfS). In addition; India is in the intermediate
endemicity zone of HBV infection (HBsAg prevalence between 2%
and 8%) harboring the second largest pool of chronic HBV infection
after China (Datta, 2008). HBV mono-infection has been extensively
studied in India (Banerjee et al., 2006a,b; Datta et al., 2008; Gandhe
et al., 2003; Kumar et al., 2005; Thakur et al., 2002; Vivekanandan
et al., 2008), however information regarding HIV–HBV co-infection is
lacking. Though a few reports have addressed seroprevalence and
associated risk groups of HIV–HBV co-infection in India (Gupta and
Singh, 2006; Saravanan et al., 2007), molecular characterization of
HBV in HIV-infected patients has not been done.
Therefore in this study, we aimed to characterize HBV genetic
heterogeneity among HIV co-infected patients from eastern India
and its possible association with the degree of immune suppres-
sion. The HBV surface gene (S) containing ‘a’ determinant region
and a partial reverse transcriptase (RT) domain of the polymerase
gene were analyzed from HBsAg positive HIV-infected patients.
Results
HBV prevalence and HBV genotypes distribution
Among 874 HIV-infected patients (622 males, 252 females;
mean age 36.5978.64; mean CD4 count 276.717226.38 cells/mm3)Fig. 1. Geographical origin of the samples collected froHBsAg was detected in 145 (16.59%) patients, which included both
anti-retroviral therapy (ART) naı¨ve as well as ART treated subjects.
Of these HIV–HBV co-infected patients, 73 (50.34%) samples
(67 males, 6 females; mean age 34.6576.92; mean CD4 count
262.157191.32 cells/mm3) could be ampliﬁed for HBV DNA from
the surface gene region. These 73 HIV-infected patients, positive
for both HBsAg and HBV DNA, were analyzed in this study. These
patients visited the ART clinic of Calcutta School of Tropical
Medicine, Kolkata from different districts of West Bengal through-
out the study period of almost two years (Fig. 1).
Three HBV genotypes [HBV/A (21/73; 28.77%), HBV/C (3/73;
4.11%) and HBV/D (49/73; 67.12%)] were detected in these HIV
co-infected patients by RFLP. When this genotype distribution
pattern was compared with that of the HBV mono-infected
patients (n¼200) coming to our laboratory, signiﬁcantly higher
prevalence of HBV/D (P¼0.03) and considerably lower frequency
of HBV/C (P¼0.001) were observed (Fig. 2A). However, HBV/A
distribution did not vary among the HIV co-infected and the HBV
mono-infected groups (28.77% vs 28.5%).The partial S gene could
be sequenced from 71 isolates for further analysis, 2 samples
were insufﬁcient and could be not sequenced.Subgenotypes of HBV: high prevalence of HBV/D2 and associated
substitutions
In the present study, HBV/A (HBV/A1) and HBV/C (HBV/C1)
isolates clustered into single subgenotype, whereas HBV/D was
distributed among four subgenotypes in the phylogenetic tree
[HBV/D1 (6/47; 12.77%), HBV/D2 (32/47; 68.08%), HBV/D3 (4/47;
8.51%) and HBV/D5 (5/47; 10.64%)] (Fig. 3A) similar to HBV mono-
infection (Fig. 2B). Interestingly, of these HBsAg/HBV-DNA positive
HIV-infected patients from eastern India, HBV/D2 solely contrib-
uted to 45.07% among all subgenotypes (32/71) and 68.08% among
the HBV/D subgenotypes. Among the HBV mono-infected samples,
only 68 HBsAg positive HBV/D isolates that could be subgenotyped
were compared with the co-infected samples. HBV/D2 isolates
circulated in highly signiﬁcant (Po0.001) proportion among them the HIV–HBV co-infected patients in this study.
Fig. 2. (A) HBV genotypes distribution in HBsAg positive HIV–HBV co-infected
patients and HBsAg positive HBV mono-infected patients from eastern India.
(B) HBV/D subgenotypes disrtibution among them. Only signiﬁcant results
(po0.05) were marked in the ﬁgure.
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infection (Fig. 2B).
Demographic, biochemical and virological parameters of the
HBV/D2 isolates were further investigated in comparison to the
non-HBV/D2 isolates (Table 1). The major HBV subgenotype
among these non-HBV/D2 isolates was HBV/A1 (21/39; 53.85%).
In addition, HBV/C1 (3/39; 7.69%), HBV/D1 (6/39; 15.38%), HBV/
D3 (4/39; 10.26%), HBV/D5 (5/39; 12.82%) were also found. In
both the groups, males were predominantly infected (490%),
sexual contact bear the highest risk of acquiring HBV infection.
However, HIV RNA load as well as serum HBV DNA load were
comparable between HBV/D2 and non-HBV/D2 group (Table 1).
The patients harboring HBV/D2 were younger than those
infected with non-HBV/D2 strains (Table 1, P¼0.028) and tended
to be more HBeAg positive compared to those with other HBV
subgenotypes (P¼0.014). Notably, the mean CD4 count was lower
in the HBV/D2 isolates than non-HBV/D2 isolates though not
statistically signiﬁcant (240.387148.42 vs 318.027339.32;
P¼0.23). (Table 1).
In the surface gene region, various immune escape mutations
were found among the HIV–HBV co-infected patients (Table 1).
Three HBV/D2 and one HBV/D5 isolates displayed a premature
stop codon at amino acid position 69 (C69stop) regardless of
HBsAg positive status. Clonal alignment conﬁrmed the presence
of C69stop by sequencing 10 clones randomly chosen from each
sample.
Further highest prevalence of HBV/D2 among the HIV–HBV co-
infected patients was conﬁrmed by phylogenetic analysis of the
polymerase RT region sequences generated from 25 subjects
(Fig. 3B). Additionally, investigation of polymerase gene region from
the 11 ART treated patients included in the study indicated the
presence of lamivudine resistant triple mutation (rtV173Lþ
rtL180MþrtM204V) in two HBV/D2 isolates and lamivudine resistant
double mutation (rtL180MþrtM204V) in one HBV/D1 subject. Thus,the two HBV/D2 isolates which harbored lamivudine mutation
rtL173V; also had vaccine escape mutation E164D in the overlapping
S gene (Table 1).
Association of HBV/D2 with CD4 count
Distribution of HBV subgenotypes was evaluated in different
CD4 count groups among these HIV co-infected patients. Inter-
estingly, an increased prevalence of HBV/D2 was found with
decreasing CD4 count (Fig. 4). Patients with CD4 count o200
cells/mm3, had highest occurrence of HBV/D2 (40.63%) while least
occurrence was observed among those with CD4 count Z500
cells/mm3 (3.13%). Moreover, the frequency of HBV/D2 isolates in
varying CD4 count groups showed a nearly signiﬁcant (Spearman
r¼0.812, P¼0.058) negative association. This correlation was
absent in non-HBV/D2 isolates (Spearman r¼0.696, P¼0.136)
as well as in its major subgenotype, HBV/A1 (Spearman
r¼0.706, P¼0.136). A major change in distribution of HBV/D2
was observed around CD4 count 350 cells/mm3. We therefore,
tried to analyze nucleotide diversity of HBV/D2 in this region. The
sample size between CD4 count o300 cells/mm3 and Z300
cells/mm3 was comparable (Fig. 4), so we performed the analysis
around CD4 count 300 cells/mm3.
Nucleotide diversity of HBV with CD4 count
When nucleotide diversity was determined among HBV/D2, the
isolates from patients with CD4 o300 cells/mm3 showed signiﬁ-
cantly decreased relative amounts of non-synonymous substitutions
(dN) in the surface gene region compared to the HBV/D2 subjects
from patients with CD4 Z300 cells/mm3 (median dN 0.004 vs 0.012
respectively, Po0.0001) without signiﬁcant difference in relative
amounts of synonymous substitutions (dS) (Fig. 5A and B). More-
over, dN/dS was also varied signiﬁcantly among the HBV/D2 isolates
in these two CD4 count groups (Fig. 5C; P¼0.001). In contrast, a
different pattern of dS and dN were observed in HBV/A1, the most
frequent subgenotype in the non-HBV/D2 group. Interestingly, no
non-synonymous substitution could be found in the HBV/A1 isolates
from patients with CD4 Z300 cells/mm3. Though negative selection
persisted (dN/dS o1) among HBV/A1 in the two CD4 count groups
similar to HBV/D2, a different dN/dS pattern was noticeable in the
surface gene region of HBV/A1 isolates (Fig. 5C).
This association of decreased non-synonymous substitutions
in the HBsAg region with lower immune pressure was consistent
in XYPLOT of cumulative behavior of average synonymous and
non-synonymous substitutions of the coding region of polymer-
ase RT domain (Supplementary data 1). In contrast, the HBV/D2
isolates from patients with CD4 Z300 cells/mm3 showed
increased non-synonymous substitutions in both the surface as
well as polymerase gene region. The difference in non-
synonymous substitutions would result in amino acid variation
which would be further reﬂected in HBV viremia.
Amino acid variation in HBV with CD4 count
Amino acid variations were measured by Shannon entropy
which reﬂected non-synonymous substitutions harbored in the
genome. In the surface gene region, a signiﬁcant difference in
median entropy was observed between the HBV/D2 isolates from
the two CD4 count groups (0.199 in CD4 o300 cells/mm3 and
0.305 in CD4 Z300 cells/mm3, P¼0.0006) (Fig. 5D). Among all
the four groups analyzed, the HBV/D2 isolates from patients with
CD4 o300 cells/mm3 showed the least median Shannon entropy.
But no signiﬁcant difference was found in median entropy
between the non-HBV/D2 isolates (P¼0.106) including HBV/A1.
Fig. 3. Phylogenetic analysis of HBV isolates from eastern Indian HIV–HBV co-infected patients (denoted by EICI) using the neighbour-joining method. Phylogenetic tree
was constructed from (A) surface gene sequences of 71 isolates and (B) polymerase RT region sequences of HBV/D2 (N¼25) isolates of this study along with reference
sequences derived from GenBank (denoted by accession numbers).
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A signiﬁcant difference was observed in HBV DNA load of the
HBV/D2 isolates in the two CD4 count groups (P¼0.03) but no
such difference in HBV viremia was found among the non-HBV/
D2 subjects in these CD4 count groups (P¼0.40) (Fig. 6). Notably,
the major non-HBV/D2 subgenotype, HBV/A1 isolates, also
demonstrated contrasting viremia in the two CD4 count groups
compared to the HBV/D2 isolates. Moreover, HBeAg positivity
was increased in the HBV/D2 subjects with low CD4 count(89.47% in oCD4 300 cells/mm3 vs 75.0% in CD4 Z300 cells/
mm3) (data not shown).Discussion
The present study sheds light on the genetic heterogeneity of
hepatitis B virus under the inﬂuence of HIV induced immune
modulation among the HIV–HBV co-infected patients from east-
ern India. To the best of our knowledge, this is the ﬁrst study from
A. Pal et al. / Virology 436 (2013) 134–142138India on genetic diversity of HBV in HIV co-infection. In the
present study, we found that the prevalence of HBV/D2, the major
HBV subgenotype among these co-infected patients, was inver-
sely associated with lowering of CD4 count. Molecular hetero-
geneity analysis of HBV/D2 revealed that the degree of immune
suppression could inﬂuence nucleotide diversity and amino acid
variation among them. The consequence was reﬂected in the
replication of HBV/D2 isolates. In contrast, HIV driven immuneTable 1
Demographic, biochemical and virological characteristics of study subjects
(N¼71).
HBV/D2 Non-HBV/D2 (A1,
C1, D1, D3 and D5)
Total no. (%) 32 (45.07) 39 (54.93)
Male (%) 29 (90.63) 36 (92.31)
Age (mean7SD)a 32.5476.88 36.4177.32
Risk factors (N) 26 31
Sexual contact (%) 15 (57.69) 22(70.97)
Blood transfusion/surgical
operation (%)
6 (23.08) 4(12.90)
Multiple exposures (%) 5 (19.23) 5(16.13)
ALT, IU/L (mean7SD) 63.90771.64 62.08727.11
CD4 count, cells/mm3 (mean7SD) 240.387148.42 318.027339.32
HIV RNA load, log copies/ml
(mean7SD)
4.4471.17 4.3671.13
HBeAg positive (%)b 25/30 (83.33) 25/37(67.57)
HBV DNA load, log copies/ml
(mean7SD)
5.371.23 5.1571.48
Amino acid substitutions in
surface gene region including
MHR(frequency)
Immune escape mutations A128V(30),Y134N/
H (1/1)
M133I/T(A1, 1/1),
M133T(C1, 1),
Q101H(C1,1),
Y134N (D1, 1),
Q129R(D1, 1)
Vaccine escape mutations E164D(2) –
Premature stop codon C69stop(3) C69stop (D5, 1)
No. of patients on ART 5 6
Lamivudine resistant mutations
(frequency)
rtL173VþrtL180MþrtM204V 2 –
rtL180MþrtM204V – 1
a P¼0.028.
b P¼0.014.
Fig. 4. Distribution of HBV/D2 isolates in varying CD4 count groups. Sample distribution
is shown in the table. a CD4 count was not available for one sample.dysfunction could modulate genetic diversity in a reverse manner
among the isolates of HBV/A1, the next frequent subgenotype
after HBV/D2.
The HBV genotypes/subgenotypes found among these co-
infected patients are consistent with our previous data on HBV
mono-infection (Banerjee et al., 2007; Chandra et al., 2009), but
the proportion differs between the HIV–HBV co-infected and the
HBV mono-infected patients of eastern India. This is in contrast to
a recent report from Mexico that showed HBV/G predominated in
the HIV co-infected patients, while HBV/H was common in the
HBV mono-infected patients (Mata Marı´n et al., 2012). In our
study, HBV/D was the predominant genotype in the HIV co-
infected patients from eastern India. Among the subgenotypes
of HBV/D, HBV/D2 circulated in signiﬁcantly higher proportion
and thus became the major HBV subgenotype. Notably, these
patients came from different parts of the state of West Bengal in
eastern India (Fig. 1); throughout the study period of almost two
years. Additionally, HBV/C1 was found rarely among these co-
infected patients. Being a recent introduction to this region
(Vivekanandan et al., 2004; Banerjee et al., 2006a), HBV/C possi-
bly have not been spread among the HIV–HBV co-infected
patients in this region.
In the present study, we observe an overall male predomi-
nance in the study subjects and an association of younger age
with the HBV/D2 isolates which are consistent with our previous
HBV mono-infection study (Chandra et al., 2009). In addition, the
HIV co-infected patients with HBV/D2 had elevated ALT level
(63.90771.64 IU/L) which is contradictory with the report by
Chandra et al. (2009) (36.81719.53 IU/L). This might be due to
the presence of HIV infection which renders hepatocytes more
prone to liver injury (Babu et al., 2009).
The key factor which induces the development of mutations in
HBV genome is the immune pressure of a host. HIV infects the
immune cells, primarily targeting the CD4þ T cells which are
eventually destroyed during the course of infection. Depletion in
the number of CD4þ T cells might be considered as a measure of
degree of immune suppression. Therefore, HIV and its associated
immune suppression might inﬂuence the molecular heterogene-
ity of the co-infecting HBV. An association between functional
immune status and HBV serological outcome in the HIV–HBV co-
infected adults was demonstrated by Landrum et al. (2010). In the
present study, the mean CD4 count was found to be lower in
the HBV/D2 subjects compared to non-HBV/D2 subjects, thoughbetween HBV/D2 and non-HBV/D2 in CD4 o300 cells/mm3 and Z300 cells/mm3
Fig. 5. Genetic diversity of HBV isolates from HIV co-infected patients with CD4 Z300 cells/mm3 and CD4 o300 cells/mm3 analyzed from partial surface gene sequences.
(A) Relative amounts of synonymous substitution (dS) and (B) non-synonymous substitution (dN) between HBV/D2 and HBV/A1 in these two CD4 count groups were
compared by Mann–Whitney U test. (C) dN/dS was compared among these groups which represented overall negative selection (dN/dS o1) of HBV in the HIV co-infected
hosts. (D) Shannon entropy among these groups showed amino acid variation harbored in that genetic region. Horizontal line within the scatter plot represented the mean.
Only signiﬁcant p values were indicated.
Fig. 6. HBV replication of HBV/D2 and non-HBV/D2 isolates in CD4 Z 300 cells/mm3
and CD4 o300 cells/mm3 represented by serumHBV load (log copies/ml). Horizontal
line within the scatter plot represented the mean.
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a trend of HBV/D2 clustering in the immunosuppressive phase
was also evident from a nearly signiﬁcant negative association
(P¼0.058) between its frequency and corresponding CD4 count.
This observation suggested that the predominance of HBV/D2
could be related to the HIV driven degree of immunosuppression.
The deciding parameter of selection in a particular environ-
ment, dN/dS, showed an overall predominance of negative selec-
tion on HBV among these HIV co-infected patients (dN/dS o1).
This supports a recent ﬁnding that identiﬁed negative selection
on HBV in the HIV co-infected patients from Caucasian ethnicity
(Audsley et al., 2010). However, it did not address whether thegenetic diversity of HBV varied with different CD4 counts. In a
recent report by Cassino et al. (2012) have suggested that as a
consequence of lower CD4 cell count, HBV subjects from HIV co-
infected patients had low quasispecies diversity as well as
evolutionary rate when compared to that from HBV mono-
infected patients. Interestingly in our study, we observed that
the molecular heterogeneity of HBV is modulated with the degree
of immune suppression and varied in different HBV
subgenotypes.
Among the HBV/D2 isolates, genetic diversity was varied sig-
niﬁcantly in the patients with CD4 Z300 cells/mm3 when com-
pared to the patients with CD4 o300 cells/mm3. The median dN
(both in the surface gene region containing B cell epitope as well as
in the polymerase gene RT region) was signiﬁcantly lower in the
later in comparison to the former. As a result, amino acid variation
was less frequently observed among the HBV/D2 subjects isolated
from patients with lower CD4 count group and they showed
reduced Shannon entropy. Thus decreased genetic diversity ren-
ders increased replication capacity to the virus resulting in higher
HBV viral load among them. Additionally, greater HBeAg positivity
was also found in the HBV/D2 infected patients with CD4 o300
cells/mm3 compared to the patients with higher CD4 count.
Taken together, it can be assumed that low CD4 count may help
the HBV/D2 isolates to retain their wild type characteristics. Thus,
the gradual decrease in CD4 count in the course of HIV co-infection
may provide increased viral ﬁtness to the HBV/D2 isolates, which
might lead to increased association of HBV/D2 with lower CD4
count. Furthermore, in an earlier HIV–HBV co-infected study
(Audsley et al., 2010), it was established that HBeAg positive status
is correlated with lower mutation frequency which supports our
results.
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HBV/D2 exhibited signiﬁcantly higher HBeAg positivity when
compared to other HBV subgenotypes. This possibly indicates
that HBV/D2 from the co-infected patients is more infectious than
other HBV subgenotypes. Due to lack of data on liver histology or
other non-invasive parameters that detects pathogenicity we are
unable to assess whether HBV/D2 is more pathogenic than the
other subgenotypes.
All of the treated patients in our study received lamivudine
as the only drug effective against HBV in their ART regimen.
Two HBV/D2 isolates among the 11 exposed to lamivudine
therapy (mean CD4 count 451.5 cells/mm3), showed the pre-
sence of lamivudine resistant polymerase gene mutation
(rtV173LþrtL180MþrtM204V) as well as corresponding vac-
cine/immune escape mutation (E164D) in the overlapping surface
gene region. Widespread use of antiretrovirals, specially the
regular use of lamivudine as a part of ART regimen in India might
predispose the emergence of polymerase mutants that result in
the development of ‘vaccine-escape’ mutants in the overlapping
surface gene region. Thus, an increased CD4 count which renders
higher dN in the HBV/D2 isolates suggests a possible emergence
of higher rate of HBV mutants to evade immune pressure. The
mutations in S gene can signiﬁcantly modify hepatitis B surface
antigen synthesis and reduce the binding efﬁciency to antibodies.
As a result, these mutants might cause even the vaccinated
individuals vulnerable to HBV infection, indicating its importance
from public health perspectives also. Thus, this study underscores
the importance for molecular monitoring of HBV in these patients
to study the incidence of such mutations, their effect on HBV-
related liver disease in the HIV co-infection, as well as their
transmission potential. Furthermore, for hepatitis B treatment
options in these patients more potent drugs, that have higher
genetic barrier against resistance development, must be seriously
considered.
Mutations in the polymerase gene may produce changes in the
overlapping surface gene region of HBV. Furthermore to evade the
host immune response, virus may develop immune escape
mutants. A128V, reported to be an immune escape mutation,
was found in most HBV/D2 isolates (30/32) in HIV co-infected
patients (Lazarevic et al., 2010). However, Tallo et al. (2008)
mentioned this substitution as a subgenotype speciﬁc substitu-
tion and thus supported our ﬁndings. In addition, several other
immune escape mutations (M133I/T, Q101H, Y134N/H and
Q129R) were also present but in very low frequency (Table 1).
Interestingly, in the upstream of ‘a’ determinant region, C69stop
was found in three HBV/D2 isolates and one HBV/D5 isolate from
HIV co-infected patients who were positive for HBsAg, HBeAg and
had higher viral load (4104 copies/ml). Recently a study has
shown the presence of this unusual stop codon in Iranian patients
with cirrhosis who were HBsAg positive with higher viremia
(Veazjalali et al., 2009). Therefore, these patients might be at a
risk of developing ESLDs.
In contrast to HBV/D2, among the non-HBV/D2 isolates genetic
diversity and viral load were modiﬁed in a different manner with
the degree of immune suppression. The non-HBV/D2 isolates
included HBV/A1 as the major subgenotype (53.85%). In the
HBV/A1 isolates, median dN was increased in the patients with
lower CD4 count (o300 cells/mm3) but surprisingly no non-
synonymous substitutions were found in the HBV/A1 isolates
with higher CD4 count i.e. CD4 Z300 cells/mm3. Differences in
the molecular heterogeneity as well as the clinical outcome
between these two HBV genotypes (HBV/D and HBV/A) has been
addressed in several previous studies (Datta et al., 2008;
Weinberger et al., 2000; Zehender et al., 2008). A possible
explanation for this contrasting substitution pattern with varying
immune suppression between HBV/A1 and HBV/D2 could be thedifference in host immune response against these two subgeno-
types. Actually, these two subgenotypes demonstrated differen-
tial expression of genes related to innate and adaptive immune
response. In our preliminary study, Cathelicidin antimicrobial
peptide (CAMP) which is reported to target enveloped virus
(Hancock and Diamond, 2000), was found to be upregulated
signiﬁcantly in HBV/A1 infection with CD4 o300 cells/mm3
compared to HBV/A1 infection with CD4 Z300 cells/mm3
(Supplementary data 2). It seems likely that in order to evade
the effect of upregulated CAMP gene, non-synonymous substitu-
tions might have been introduced in HBV/A1genome. In contrast,
CAMP gene is downregulated signiﬁcantly in HBV/D2 isolates
with lower CD4 count where decreased non-synonymous sub-
stitutions were observed. This variation between HBV/A1 and
HBV/D2 was noted in the surface gene, which is the major target
of neutralizing antibody for immune-clearance; however study
from the whole genome might help in better understanding of
this phenomenon.
In conclusion, HBV/genotype-D and HBV/subgenotype-D2 pre-
dominantly circulated among the HIV co-infected patients in
eastern India. The notable ﬁndings of this study include a trend
of negative association of frequency of the HBV/D2 isolates with
CD4 counts and modiﬁcation of HBV molecular heterogeneity by
HIV driven immune dysfunction particularly the degree of
immune suppression. Being associated with decreased genetic
variability and increased viremia in low CD4 count, selection of
HBV/D2 seems to be favored in isolates with low CD4 count.
Increased non-synonymous substitutions with moderate increase
in CD4 count also suggests that ART induced immune reconstitu-
tion might lead to the development of vaccine/immune escape
and lamivudine resistant mutations among them. In contrast to
HBV/D2, interestingly in HBV/A1 genetic variability is modiﬁed
differently in presence of HIV. Further work is needed to conﬁrm
the role of HIV on HBV evolution by prospective studies. Taken
together, our study emphasizes the necessity for molecular
monitoring of HBV and use of potent antivirals that reduce the
risk of HBV mutations development, in the setting of HIV co-
infection.Material and methods
Study participants
A total of 874 HIV-infected patients coming to the ART clinic of
Calcutta School of Tropical Medicine, Kolkata were referred to
ICMR Virus Unit, Kolkata for testing HBV markers during March
2010–December 2011.They were initially screened for HBsAg
status followed by tested for detection of HBV DNA among HBsAg
positive patients. Among them 73 HIV-infected patients were
positive for both HBsAg and HBV DNA and they were included in
the study. HCV positive patients were excluded from the study.
Among the study subjects, 11 patients were exposed to anti-
retroviral therapy (ART including Lamivudine) with median
duration of two years. After obtaining informed consent, blood
samples were collected from the patients. Plasma was separated
on the same day of collection and was stored at 80 1C in
aliquots until further analysis. Ethical clearance was obtained
from the Ethics committee of the Institution.Serological assays
HBsAg and HBeAg were tested by commercial EIA kits (Dia-
sorin, S.P.A., Saluggia, Italy) according to manufacturer’s instruc-
tions. Anti-HIV and anti-HCV were screened using kits from
A. Pal et al. / Virology 436 (2013) 134–142 141General Biologicals, Taiwan and Hepanostika, Boxtel, The Nether-
lands respectively.
DNA isolation, HBV DNA detection and genotyping
DNA was extracted from 200 ml of plasma using the QIAamp
DNA Blood MiniKit (QIAgen, Hilden, Germany). HBV DNA was
detected by nested-PCR ampliﬁcation from the surface gene
region as reported by Datta et al. (2006). Hemi-nested-PCR
followed by restriction fragment length polymorphism (RFLP)
was done to determine HBV genotypes as descried previously
(Biswas et al., 2009). For avoiding false positive results guidelines
by Kwok and Higuchi (1989) were strictly followed.
Ampliﬁcation of RT region of polymerase gene
Reverse transcriptase (RT) region of HBV polymerase (pol)
gene was ampliﬁed using AmpliTaq Gold DNA polymerase
(Applied Biosystems, Foster City, CA,USA) by nested polymerase
chain reaction (PCR). Six microlitre of the extracted DNA was
added in 30 ml reaction mix of the ﬁrst round PCR using primers
HB1F [50-AAGCTCTGCTAGATCCCAGAGT-30 (sense 18–39)]; HB6R
[50-AACAGACCAATTTATGCCTA-30 (antisense 1803–1784)] and
4 ml from the ﬁrst round PCR product was ampliﬁed using primers
NIV3 [50-GACTCGTGGTGGACTTCTCTC-30 (sense 251–271)] and
HS4R [50-CATACTTTCCAATCAATAGG-30 (antisense 989–970)].
The nucleotide sequence numbering was according to the sug-
gested reference strain sequence EI03188 [Genbank accession
number DQ315783] (India). The thermal cycling proﬁle included
incubation for 10 min at 95 1C, 45cycles at 95 1C for 50 s, 55 1C for
45 s, and 72 1C for 45 s, followed by a ﬁnal extension step at 72 1C
for 7 min. Second round PCR followed the same proﬁle for 40
cycles.
Sequence analysis of surface gene/polymerase gene region and
determination of subgenotypes
Ampliﬁed surface gene region for 115 amino acids including ‘a’
determinant region and 190 amino acids of polymerase RT region
were sequenced directly using Prism Big Dye kit in ABI 3130xl
Genetic Analyzer (Applied Biosystems, Foster City, CA,USA) and
analyzed using Bioedit version 7.0.9.0 (Hall, 1999). HBV geno-
types/subgenotypes and sequence substitutions were analyzed by
aligning study sequences with Genbank retrieved sequences.
Phylogenetic analysis was performed in Mega 4, using the
neighbour-joining method (Tamura et al., 2007). Phylogenetic
groups were evaluated by the bootstrap test with 1000 replicates.
The nucleotide sequence data reported in this article have
been submitted to the DDBJ/EMBL/GenBank. Accession numbers
for the HBV partial surface gene sequences: JQ284305–JQ284375.
Accession numbers for the HBV partial polymerase gene
sequences: JQ349118–JQ349146 and JX244153-JX244171.
Genetic diversity calculation
Genetic diversity was determined from nucleotide diversity
followed by amino acid variation in HBV surface gene and
polymerase gene region. Nucleotide diversity was evaluated by
the number of synonymous substitutions per synonymous site
(dS) and the number of non-synonymous substitutions per non-
synonymous site (dN). These relative amounts were estimated by
the method of Nei and Gojobori using sequence analysis
tool—SNAP available at the Los Alamos National Laboratory
website (/http://www.hiv.lanl.gov/content/sequence/SNAP/
SNAP.htmlS) (Korber, 2000). The ratio of dN and dS (dN/dS)
was calculated to estimate selection (Negative selection if dN/dSo1 and Positive selection if dN/dS 41). The cumulative behavior
of average synonymous and non-synonymous substitutions of a
coding region was automatically generated by SNAP as XYPLOT.
The Shannon entropy per site was determined from the deduced
amino acid sequences of ampliﬁed gene region using the Entropy
program on this Los Alamos National Laboratories website
(/http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy.
htmlS) as an indicator of amino acid variation.
Ligation, cloning of PCR products
PCR products of the surface gene region were cloned using
InsTA clone PCR cloning kit, (MBI Fermentas, Vilnius, Lithuania).
DNA from transformed colonies were ampliﬁed and sequenced as
mentioned above.
Quantiﬁcation of HBV DNA and HIV RNA
HBV DNA was quantiﬁed by TaqMan based real time PCR assay
in Applied Biosystems SDS 7000 (Foster City, CA, USA) with lower
detection limit of 102 copies/ml (Chandra et al., 2007). Quantiﬁ-
cation of HIV RNA was measured by COBAS TaqMan HIV-1 test in
COBAS Taqman 48 analyzer using human plasma. Lower detec-
tion limit was 47 copies/ml.
Statistical analysis
Statistical calculations representing the continuous data
were expressed as the mean value7standard deviation (SD).
Mann–Whitney U test, unpaired t test were performed for com-
parisons of continuous variables between the groups using the
Graphpad Prism (version 4.0.3). Categorical variables were ana-
lyzed using the chi-square test or Fisher exact test, as appropriate.
Correlation was analyzed by Spearman’s rank test. All P-values
were 2-tailed and P-value o0.05 was considered to be signiﬁcant.Acknowledgments
We specially extend our gratitude to the staffs of our Unit and
all participants in our study. We thank Pulak Adak and Chinmoy
Mondal for excellent technical assistance.
This work is supported by research grant from Department of
Biotechnology (DBT), Government of India. Grant sanction no. BT/
PR14485/Med/29/203/2010. Ananya Pal received NET JRF fellow-
ship from Council of Scientiﬁc and Industrial Research (CSIR),
India (CSIR Sanction No. 09/975(0002)/2010-EMR-I).Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2012.11.003.References
Audsley, J., Littlejohn, M., Yuen, L., Sasadeusz, J., Ayres, A., Desmond, C., Spelman,
T., Lau, G., Matthews, G.V., Avihingsanon, A., Seaberg, E., Philp, F., Saulynas, M.,
Ruxrungtham, K., Dore, G.J., Locarnini, S.A., Thio, C.L., Lewin, S.R., Revill, P.A.,
2010. HBV mutations in untreated HIV–HBV co-infection using genomic
length sequencing. Virology 405, 539–547.
Babu, C.K., Suwansrinon, K., Bren, G.D., Badley, A.D., Rizza, S.A.., 2009. HIV induces
TRAIL sensitivity in hepatocytes. PLoS One 4, e4623.
Banerjee, A., Datta, S., Chandra, P.K., Roychowdhury, S., Panda, C.K., Chakravarty, R.,
2006a. Distribution of hepatitis B virus genotypes: phylogenetic analysis and
virological characteristics of Genotype C circulating among HBV carriers in
Kolkata, Eastern India. World J. Gastroenterol. 12, 5964–5971.
A. Pal et al. / Virology 436 (2013) 134–142142Banerjee, A., Kurbanov, F., Datta, S., Chandra, P.K., Tanaka, Y., Mizokami, M.,
Chakravarty, R., 2006b. Phylogenetic relatedness and genetic diversityof
hepatitis B virus isolates in eastern India. J. Med. Virol. 78, 1164–1174.
Banerjee, A., Chandra, P.K., Datta, S., Biswas, A., Bhattacharya, P., Chakraborty, S.,
Chakrabarti, S., Bhattacharya, S.K., Chakravarty, R., 2007. Frequency and
signiﬁcance of hepatitis B virus surface gene variant circulating among
‘antiHBc only’ individuals in Eastern India. J. Clin. Virol. 40, 312–317.
Biswas, A., Chandra, P.K., Datta, S., Panigrahi, R., Banerjee, A., Chakrabarti, S.,
Biswas, K., Patra, D., Bhattacharya, P., Biswas, K., Chakravarty, R., 2009.
Frequency and distribution of hepatitis B virus genotypes among eastern
Indian voluntary blood donors: association with precore and basal core
promoter mutations. Hepatol. Res. 39, 53–59.
Cassino, L., Torres, C., Mbayed, V., Laufer, N., Campos, R.H., Quarleri, J., 2012.
Comparative analysis of hepatitis B virus genotype a molecular evolution in
patients infected with HBV and in patients co-infected with HBV and HIV. J.
Med. Virol. 84, 562–569.
Chandra, P.K., Banerjee, A., Datta, S., Chakravarty, R., 2007. G1862T mutation
among hepatitis B virus-infected individuals: association with viral genotypes
and disease outcome in Kolkata, Eastern India. Intervirology 50, 173–180.
Chandra, P.K., Biswas, A., Datta, S., Banerjee, A., Panigrahi, R., Chakrabarti, S., De,
B.K., Chakravarty, R., 2009. Subgenotypes of hepatitis B virus genotype D (D1,
D2, D3 and D5) in India: differential pattern of mutations, liver injury and
occult HBV infection. J. Viral. Hepatitis 16, 749–756.
Datta, S., 2008. An overview of molecular epidemiology of hepatitis B virus (HBV)
in India. Virol. J. 5, 156.
Datta, S., Banerjee, A., Chandra, P.K., Chowdhury, A., Chakravarty, R., 2006.
Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis
B virus (HBV) infection in families of asymptomatic HBsAg carriers. J. Med.
Virol. 78, 53–59.
Datta, S., Biswas, A., Chandra, P.K., Banerjee, A., Panigrahi, R., Mahapatra, P.K.,
Chakrabarti, S., Panda, C.K., Chakravarty, R., 2008. Molecular epidemiology and
clinical signiﬁcance of hepatitis B virus genotypes, core promoter and precore
mutations in eastern India. Intervirology 51, 275–284.
Gandhe, S.S., Chadha, M.S., Arankalle, V.A., 2003. Hepatitis B virus genotypes and
serotypes in western India: lack of clinical signiﬁcance. J. Med. Virol. 69,
324–330.
Gupta, S., Singh, S., 2006. Hepatitis B and C virus co-infections in human
immunodeﬁciency virus positive North Indian patients. World J. Gastroen-
terol. 12, 6879–6883.
Hall, T.A., 1999. Bioedit: a user-friendly biological sequence alignment editor and
analysis program for windows 95/98/NT. Nucleic Acids Symp. Ser. 41, 95–98.
Hancock, R.E., Diamond, G., 2000. The role of cationic antimicrobial peptides in
innate host defences. Trends Microbiol. 8, 402–410.
Korber, B., 2000. HIV signature and sequence variation analysis. In: Rodrigo, A.G.,
Learn, G.H. (Eds.), Computational Analysis of HIV Molecular Sequences. Kluwer
Academic Publishers, Netherlands, pp. 55–72. (Chapter 4).
Kumar, A., Kumar, S.I., Pandey, R., Naik, S., Aggarwal, R., 2005. Hepatitis B virus
genotype A is more often associated with severe liver disease in Northern
India than is genotype D. Indian J. Gastroenterol. 24, 19–22.
Kwok, S., Higuchi, R., 1989. Avoiding false positives with PCR. Nature 339,
237–238.
Lacombe, K., Boyd, A., Gozlan, J., Lavocat, F., Girard, P.M., Zoulim, F., 2010. Drug-
resistant and immune-escape hepatitis B virus mutants in HIV-infected hosts.
Antiviral Ther. 15, 493–497.
Lacombe, K., Massari, V., Girard, P.M., Serfaty, L., Gozlan, J., Pialoux, G., Mialhes, P.,
Molina, J.M., Lascoux-Combe, C., Wendum, D., Carrat, F., Zoulim, F., 2006.
Major role of hepatitis B genotypes in liver ﬁbrosis during coinfection with
HIV. AIDS 20, 419–427.
Landrum, M.L., Fieberg, A.M., Chun, H.M., Crum-Cianﬂone, N.F., Marconi, V.C.,
Weintrob, A.C., Ganesan, A., Barthel, R.V., Wortmann, G., Agan, B.K., 2010. The
effect of human immunodeﬁciency virus on hepatitis B virus serologic status
in co-infected adults. PLoS One 5, e8687.
Lazarevic, I., Cupic, M., Delic, D., Svirtlih, N.S., Simonovic, J., Jovanovic, T., 2010.
Prevalence of hepatitis B virus MHR mutations and their correlation with
genotypes and antiviral therapy in chronically infected patients in Serbia.
J. Med. Virol. 82, 1160–1167.
Lin, C.L., Kao, J.H., 2011. The clinical implications of hepatitis B virus genotype:
recent advances. J. Gastroenterol. Hepatol. 26, 123–130.Mata Marı´n, J.A., Arroyo Anduiza, C.I., Caldero´n, G.M., Cazares Rodrı´guez, S.,
Fuentes Allen, J.L., Arias Flores, R., Gayta´n Martı´nez, J., 2012. Prevalence and
resistance pattern of genotype G and H in chronic hepatitis B and HIV co-
infected patients in Mexico. Ann. Hepatol. 11, 47–51.
Puoti, M., Torti, C., Bruno, R., Filice, G., Carosi, G., 2006. Natural history of chronic
hepatitis B in co-infected patients. J. Hepatol. 44, S65–S70.
Salmon-Ceron, D., Rosenthal, E., Lewden, C., Bouteloup, V., May, T., Burty, C.,
Bonnet, F., Costagliola, D., Jougla, E., Semaille, C., Morlat, P., Cacoub, P., Cheˆne,
G., ANRS EN19 Mortalite´ Study Group and Mortavic, 2009. Emerging role of
hepatocellular carcinoma among liver-related causes of deaths in HIV-infected
patients: The French national Mortalite´ 2005 study. J. Hepatol. 50, 736–745.
Saravanan, S., Velu, V., Kumarasamy, N., Nandakumar, S., Murugavel, K.G.,
Balakrishnan, P., Suniti, S., Thyagarajan, S.P., 2007. Coinfection of hepatitis B
and hepatitis C virus in HIV-infected patients in south India. World J.
Gastroenterol. 13, 5015–5020.
Soriano, V., Vispo, E., Labarga, P., Medrano, J., Barreiro, P., 2010. Viral hepatitis and
HIV co-infection. Antiviral Res. 85, 303–315.
Tallo, T., Tefanova, V., Priima¨gi, L., Schmidt, J., Katargina, O., Michailov, M.,
Mukomolov, S., Magnius, L., Norder, H., 2008. D2: major subgenotype of
hepatitis B virus in Russia and the Baltic region. J. Gen. Virol. 89, 1829–1839.
Tamura, K., Dudley, J., Nei, M., Kumar, S., 2007. MEGA4: molecular evolutionary
genetics analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24, 1596–1599.
Thakur, V., Guptan, R.C., Kazim, S.N., Malhotra, V., Sarin, S.K., 2002. Proﬁle,
spectrum and signiﬁcance of HBV genotypes in chronic liver disease patients
in the Indian subcontinent. J. Gastroenterol. Hepatol. 17, 165–170.
Thio, C.L., 2009. Hepatitis B and human immunodeﬁciency virus coinfection.
Hepatology 49, S138–S145.
Thio, C.L., Seaberg, E.C., Skolasky Jr., R., Phair, J., Visscher, B., Mun˜oz, A., Thomas,
D.L., 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the
multicenter cohort study (MACS). Lancet 360, 1921–1926.
Vallet-Pichard, A., Pol, S., 2004. Hepatitis viruses and human immunodeﬁciency
virus co-infection: pathogenesis and treatment. J. Hepatol. 41, 156–166.
Veazjalali, M., Norder, H., Magnius, L., Jazayeri, S.M., Alavian, S.M., Mokhtari-Azad,
T., 2009. A new core promoter mutation and premature stop codon in the S
gene in HBV strains from Iranian patients with cirrhosis. J. Viral Hepatitis 16,
259–264.
Vivekanandan, P., Abraham, P., Sridharan, G., Chandy, G., Daniel, D., Raghuraman,
S, Daniel, H.D., Subramaniam, T., 2004. Distribution of hepatitis B virus
genotypes in blood donors and chronically infected patients in a tertiary care
hospital in southern India. Clin. Infect. Dis. 38, e81–e86.
Vivekanandan, P., Bissett, S., Ijaz, S., Teo, C.G., Sridharan, G., Raghuraman, S.,
Daniel, H.D., Kavitha, M.L., Daniel, D., Chandy, G.M., Abraham, P., 2008.
Correlation between hepatitis B genotypes, 1896 precore mutation, virus
loads and liver dysfunction in an Indian population. Indian J. Gastroenterol.
27, 142–147.
Weinberger, K.M., Bauer, T., Bo¨hm, S., Jilg, W., 2000. High genetic variability of the
group-speciﬁc a-determinant of hepatitis B virus surface antigen (HBsAg) and
the corresponding fragment of the viral polymerase in chronic virus carriers
lacking detectable HBsAg in serum. J. Gen. Virol. 81, 1165–1174.
Zehender, G., De Maddalena, C., Giambelli, C., Milazzo, L, Schiavini, M., Bruno, R.,
Tanzi, E., Galli, M., 2008. Different evolutionary rates and epidemic growth of
hepatitis B virus genotyps A and D. Virology 380, 84–90.Web References
/http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy.htmlS (last accessed
10.7.12.).
/http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.htmlS (last accessed 10.7.12.).
/http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/progressre
ports/2010countries/india_2010_country_progress_report_en.pdfS (last accessed
19.7.12.).
/http://www.unaids.org/documents/20101123_GlobalReport_Chap2_em.pdfS
(last accessed 9.10.12.).
